Compare Ascendis Pharma A/S (ASND) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Occidental Petroleum Corporation — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Occidental Petroleum Corporation trades at $53.71 (market cap $52.61B). The key difference: Occidental Petroleum Corporation is far larger — about 3× Ascendis Pharma A/S's market cap, and Occidental Petroleum Corporation pays a 1.97% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OXY | |
|---|---|---|
Market Cap | $17.74B | $52.61B |
Sector | Health | Energy |
52-Week High | $277.18 | $66.24 |
52-Week Low | $163.32 | $38.92 |
Enterprise Value | $18.11B | $73.69B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Occidental Petroleum (OXY) trades at $52.89, up 1.13% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust profitability with a 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent news highlights rising oil prices from Middle East tensions boosting realized prices, while debt reduction and CrownRock asset integration remain focal points.
Outlook is mixed: analyst consensus is bullish with a $65.86 price target (50% buy ratings), but high P/E of 71.47 suggests premium valuation. Key opportunities include oil price leverage and carbon capture initiatives; risks involve oil volatility, debt levels, and execution under new CEO Richard Jackson. Cash flow trends show variability, with 2026 projecting positive net cash flow of $1.2B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
